All In Biotech

Drug Trial Radar · NCT04997902

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Dec 7, 2021

Primary completion

Aug 29, 2025

Study completion Aug 29, 2025

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.

Conditions

  • HNSCC

Interventions

  • TipifarnibDrug

    Oral administration

  • AlpelisibDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: First 28 days (1 cycle) of combination therapy
  2. Descriptive statistics of Adverse Events (AEs)Time frame: From Cycle 1 Day 1 until 30 days after last trial intervention dose or 30 days after trial completion, whichever comes first, assessed up to 2 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Lake Nona DDU (Florida Cancer Specialists)

    Orlando, Florida

  • University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center)

    Baltimore, Maryland

  • Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center)

    Baltimore, Maryland

  • Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center)

    Boston, Massachusetts

  • Washington University, School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center)

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.